BG-89894 / CSPC Pharma, BeOne Medicines - LARVOL DELTA

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=237 | Recruiting | Sponsor: BeiGene | N=92 ➔ 237 | Trial completion date: Nov 2026 ➔ Jun 2027 | Trial primary completion date: Nov 2026 ➔ Jun 2027

Enrollment change • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=140 | Recruiting | Sponsor: BeiGene | Trial completion date: Dec 2026 ➔ Dec 2028

Trial completion date • Oncology • Solid Tumor

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of SYH2039 Tablets in Adults with Advanced Solid Tumors (ChiCTR) - P1 | N=186 | Recruiting | Sponsor: Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences); Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sci

New P1 trial • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MTAP

Study of SYH2039 in Participants with Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=186 | Recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor (Businesswire) - "BeiGene...announced it has entered into a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology...for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors....'This MAT2A inhibitor is a valuable addition to our solid tumor pipeline, and we’re eager to explore its potential, particularly in combination with our internally developed PRMT5 inhibitor, BGB-58067'....BGB-58067, which is on track to enter the clinic before the end of the year, is designed to avoid on-target hematological toxicity seen with first-generation PRMT5 inhibitors....Under the terms of the agreement, BeiGene has an exclusive license to develop, manufacture and commercialize SYH2039 worldwide. CSPC will receive upfront and time-based payments totaling $150 million and will be eligible for payments upon the achievement of certain development and commercial milestones and tiered royalties."

Licensing / partnership • New trial • Solid Tumor

Study of SYH2039 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=186 | Not yet recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor